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LETTERS TO THE EDITOR
Idarucizumab Dosing in Kidney Failure
To the Editor:

In the case report by Novak et al,1 their use of a single
idarucizumab dose and blood product therapy merits
further discussion. We believe that idarucizumab dosing
should be based on serial clinical assessments (eg, vital
signs, hemorrhage site, and patient’s response to therapy)
and a profile of clotting times at least every 6 to 8 hours
(eg, ecarin clotting time, thrombin clotting time, activated
clotting time, and activated partial thromboplastin time) in
addition to blood component therapy, as in the clinical
scenario described by Novak et al.
Dabigatran is redistributed from peripheral tissues into
the intravascular compartment following idarucizumab
therapy.1-4 Resurgence of dabigatran activity occurs after
about 6 to 8 hours in patients with acute kidney injury or
kidney failure.1-3 Dabigatran does not discriminate between endogenous or exogenous sources of thrombin.
Thrombin derived from blood component therapy (eg,
prothrombin complex concentrate, activated prothrombin
complex concentrate, or fresh frozen plasma) will be
inhibited unless dabigatran activity has been neutralized.
This suggests that the effectiveness of therapy should be
assessed by serial clinical assessments and a profile of
clotting times at least every 6 to 8 hours, with additional
blood component and idarucizumab therapy as clinically
indicated. In the REVERSE-AD study, 1.8% of patients
received 10 to 15 g of idarucizumab,4 while its product
label indicates an additional 5-g dose of idarucizumab may
be considered.5
The data for nonspecific prohemostatic agents are
methodologically limited, but it is reasonable to administer
blood component therapy to a patient with serious hemorrhaging due to excessive dabigatran activity based on
in vitro and preclinical data.6 Although the discrepancies
between some of the animal data and data for humans may
be due to different measured end points, these data suggest
prothrombin complex concentrate and activated prothrombin complex concentrate to be more effective than
fresh frozen plasma.6 In select patients, the need to
establish effective hemostasis using blood component and
idarucizumab therapy outweighs the potential risk for
thrombotic adverse events in patients who are
hemorrhaging.
Luke Yip, MD
Jou-Fang Deng, MD
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In Reply to ‘Idarucizumab Dosing in
Kidney Failure’
We thank Drs Yip and Deng1 for their insights on our
case report.2 We agree that frequent clinical and laboratory
assessment in a patient with life-threatening hemorrhage is
essential. Clinical examination of this critically ill patient
was constant, and coagulation parameters were measured
10 times during his 3-day hospital course (approximately
every 4 hours). We also agree that repeat dosing of idarucizumab may have been beneficial had it been possible, as
in the report we cited of dabigatran toxicity in acute kidney injury (AKI).
The administration of prothrombin complex concentrates (PCCs) to reverse bleeding in patients with end-stage
liver disease (ESLD) has not been rigorously investigated.
Drs Yip and Deng note that PCCs attenuated hemorrhage in
mice receiving dabigatran, but a recent report suggests that
PCCs may have worsened bleeding in a patient with ESLD.3
In that report, as in our case, the patient developed coagulopathy and AKI requiring hemodialysis catheter insertion. PCC administration resulted in disseminated
intravascular coagulation, with epistaxis, expanding hematomas, and oozing from the vascular access site. Separately, although one ex vivo experiment showed that PCCs
restored thrombin generation in plasma previously taken
from patients receiving dabigatran, a small randomized
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trial showed that PCCs had no effect on coagulation parameters in such patients in vivo.4,5 Importantly, these
individuals had normal liver and kidney function. A trial of
PCCs in patients with ESLD with coagulopathy has been
proposed, but until more robust clinical data are available,
PCCs should be used cautiously to manage hemorrhage in
patients with ESLD and AKI.6
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